A 7-H-PYRROLO[2,3-D]PYRIMIDINE JAK INHIBITOR.

Abstract

This disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of utilizing the crystalline forms, and processes for preparing the crystalline forms.

Description

Cross-reference to related applications This application claims priority over U.S. provisional application 62 / 837972, filed on April 24, 2019, the contents of which are incorporated herein by reference in their entirety. Technical field of the invention This disclosure relates to polymorphs of 2-(3-(4-(7H-pyrrolo[2,3-c]pyrimidin-44l)-1 Hpyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, to pharmaceutical compositions and processes for preparing these, and to methods of using these, for example, for the treatment of dermatological conditions. Background of the invention International application publication WO / 2009 / 114512 discloses certain JAK inhibitors, including the compound 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]p¡nm¡din-44l)-1H-pyrazol-1-l)-1-(cycloprop¡lsulfon¡l)azetidin3-l)acetonitrile (Example 80), its preparation as a trifluoroacetic acid salt (Example 2) and as a phosphoric acid salt (Example 81). Brief description of the invention 2-(3-(4-(7 / - / -pyrrolo[2,3-c(pyrimidin-4-1)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile is needed that can be used efficiently, safely, and reproducibly, and methods of preparation and purification that can be used efficiently and reproducibly on a large scale for industrial manufacturing. In particular, crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c(pyrimidin-4-1)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile is needed that can be used efficiently, safely, and reproducibly, and methods of preparation and purification that can be used efficiently and reproducibly on a large scale for manufacturing industrial.More particularly, polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3c / jpyrimidin-4-1l)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is needed in a large quantity that can be used efficiently, safely and reproducibly, and methods of preparation and purification that can be used efficiently and reproducibly on a large scale for industrial manufacturing. In certain embodiments, the present disclosure provides a largely polymorphically pure crystalline form I of 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile and processes for preparing it. In certain embodiments, the present disclosure provides a largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile and processes for preparing it. In certain embodiments, the present disclosure provides a largely polymorphically pure form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 H-pyrazol-1 -yl)-1 (cyclopropylsulfonyl)azetidin-3-yl)acetonitrile and processes for preparing this. In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a largely polymorphically pure form I of 2-(3-(4-(7 / - / -pyrrolo[2,3-c]primidine-4-1)1 H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-4)acetonitrile and a pharmaceutically acceptable excipient. In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a largely polymorphically pure form II of 2-(3-(4-(7 / - / -pyrrolo[2,3-d]primidine-4-1)1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile and a pharmaceutically acceptable excipient. In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a largely polymorphically pure form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]p¡r¡d¡n-4-¡l)1 / 7-p¡razol-14l)-1-(cycloprop¡lsulfonyl)azet¡d¡n-3-¡l)acetonitrile and a pharmaceutically acceptable excipient. In certain embodiments, this disclosure provides a method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of largely polymorphically pure Form I of 2-(3-(4-(7H-pyrrolo[2,3-d]primidin-4-1)-1 / 7-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile. In certain embodiments, this disclosure provides a method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of largely polymorphically pure Form II of 2-(3-(4-(7H-pyrrolo[2,3-d]primidin-4-1)-1 / 7-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile.In certain embodiments, the present disclosure provides a method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of the largely polymorphically pure form III of 2-(3-(4-(7 / - / -pyrolo[2,3-d]pyrimidin-4-1)-1 / - / -pyrazol-141)-1 (cyclopropylsulfonyl)azetidine-3-yl)acetonitrile. In certain embodiments, the present disclosure provides a process for preparing 2-(3-(4-(7 / - / pyrolo[2,3-d]p¡nmid¡n-4-¡l)-1 / - / -pyrazol-141)-1 -(cyclopropylsulfon¡l)azetidin-34l)acetonitrile and intermediates thereof. Detailed description of the invention This disclosure relates to a compound, 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-44l)-1 / - / pyrazol-14l)-1-(cyclopropylsulfonyl)azetidine-34l)acetonitrile, polymorphs thereof identified herein as form I, form II and form III and pharmaceutical compositions thereof and methods of use of the polymorphs, for example, for the treatment of dermatological conditions, methods of preparation of polymorphs and methods of preparation of the compound and intermediates thereof. 1. Definitions Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly assigned to them by a person skilled in the art. In case of conflict, this document, including its definitions, shall prevail. Preferred methods and materials are described below, although similar or equivalent methods and materials may be used in the implementation or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are for illustrative purposes only and are not intended to be limiting. The terms “comprises,” “includes,” “having,” “has,” “may,” “contains,” and variants thereof are intended to be open transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “one,” and “the” include plural references unless the context clearly indicates otherwise. This disclosure also contemplates other realizations “comprising,” “consisting of,” and “essentially consisting of” the realizations or elements presented herein, whether explicitly stated or not. The term “approximately” when used in relation to a measurable numerical variable, refers to the stated value of the variable and all values ​​of the variable that are within the experimental error of the stated value or within ± 10 percent of the stated value, whichever is greater. The term “acceptable excipient” refers to those materials normally used in the preparation of veterinary and pharmaceutical compositions. These materials must be pure and non-toxic in the quantities used. They are generally solid, semi-solid, or liquid materials that, when added together, can act as a vehicle or medium for the active ingredient. Examples of acceptable excipients can be found in Remington's Pharmaceutical Sciences and the Handbook of Pharmaceutical Excipients. These include diluents, vehicles, carriers, ointment bases, binders, disintegrants, lubricants, glidants, sweetening agents, flavoring agents, gel bases, sustained-release matrices, stabilizing agents, preservatives, solvents, suspending agents, lamps, emulsifiers, colorants, propellants, coating agents, and others. The term “aromatic solvent” refers to a benzene optionally substituted with one or two substituents selected from the group consisting of methyl, chloro, bromo, cyano, nitro, and aceto. The term “aromatic solvent” specifically includes nitrobenzene, chlorobenzene, toluene, xylene, and acetophenone. The expression “C1-5 alcohol” refers to a linear or branched alkanol that has from one to five carbon atoms, for example, methanol, ethanol, n-propanol, isopropanol, 1-butanol, ethylene glycol, 1,3-propanediol and the like. The expression “C1-C4 alkyl” refers to a linear or branched alkyl chain having one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl and the like. The expression “C2-8 alkyl ether” refers to a linear, branched or cyclic alkyl ether that has a total of two to eight carbon atoms, for example dimethyl ether, diethyl ether, f-butyl methyl ether, THF, 2-methyl-THF, dioxane and the like. The expression “C3-8 alkyl acetate” refers to linear or branched alkyl esters of acetic acid having a total of three to eight carbons, for example, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate and the like. The expression “C2-5 alkyl cyanide” refers to linear or branched alkyl cyanides that have a total of two to five carbon atoms, for example, acetonitrile, propionitrile, and butyronitrile. The expression “C3-9 alkyl ketone” refers to a linear, branched, or cyclic alkyl group that has an oxo group and has a total of three to nine carbon atoms, for example, acetone, methyl ethyl ketone, and cyclohexanone. The expression “Cs-s hydrocarbon” refers to a linear, branched or cyclic saturated alkyl hydrocarbon, for example, pentane, hexane, heptane, octane, cyclopentane, cyclohexane, methylcyclohexane and the like. The expression “5-6 member heterocyclic ring” refers to a 5- to 6 member monocyclic saturated ring that includes the oxygen atoms to which R1 and R2 are attached and the boron to which those oxygen atoms are attached. The terms “crystallize,” “crystallizing,” “crystallization,” and similar terms refer to complete dissolution followed by precipitation and slurry formation processes that do not result in complete dissolution. Slurry processes include those that involve the continuation of the crystallization process after precipitation following complete dissolution. The expression “dermatological conditions” includes skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions. The term “effective quantity” refers to the quantity or dose of the compound of the invention, or a pharmaceutically acceptable salt thereof, which, upon administration of a single or multiple doses to the patient, produces the desired effect in the patient for diagnosis or treatment. The attending physician responsible for the diagnosis, as well as a person skilled in the art, can readily determine an effective quantity by using known techniques and observing the results obtained under similar circumstances.In determining the effective amount for a patient, the attending physician in charge of the diagnosis considers a number of factors, including, but not limited to: the patient's species or non-human mammal; their size, age, and general health; the specific disease or disorder involved; the degree, involvement, or severity of the disease or disorder; the individual patient's response; the particular compound administered; the route of administration; the bioavailability characteristics of the administered preparation; the selected dosage regimen; the use of concurrent medication; and other relevant circumstances. The terms “patient,” “subject,” and “non-human mammal” refer to a warm-blooded animal, such as dogs, cats, mice, rats, guinea pigs, rabbits, cows, horses, sheep, goats, and pigs. Pets or companion animals, such as dogs and cats, as well as mice, guinea pigs, and rabbits, are specific examples of non-human mammals. The preferred non-human mammals are dogs and cats. Ideally, the non-human mammal is a canine. A particularly preferred non-human mammal is the dog. The term “salt” refers to veterinary or pharmaceutically acceptable salts of organic acids and bases or inorganic acids and bases. Such salts are well known in the art and include those described in the Journal of Pharmaceutical Science, 66, 2-19 (1977). An example is the hydrochloride salt. The term, as used herein, expressly excludes a trifluoroacetic acid salt and a phosphoric acid salt. The expression “largely polymorphically pure” refers to a polymorphic purity greater than 90%, preferably greater than 97%, more preferably greater than 99%, and even more preferably greater than 99.5%. The terms “treat” or “that treats” refer to restricting, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder. The expression “water activity” is equal to ap / p' where p is the partial pressure of water vapor in the solution, and p* is the partial pressure of pure water vapor at the same temperature. For the enumeration of numerical intervals herein, each intermediate number between them is explicitly considered with the same degree of precision. For example, for the interval 92-97, the numbers 93, 94, 95, and 96 are considered in addition to 92 and 97, and it is explicitly stated that the numbers 92.1, 92.2, 92.3, 92.4, 92.5, 92.6, etc., up to 97.0 are included in the interval. 2. Compounds The compounds of the invention include crystalline forms I, II, and III of 2-(3-(4-(7 / 7-pyrrolo[2,3d]pyrimidin-4-1)-1 / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile. Crystalline forms of 2-(3-(4-(7 / 7-pyrrolo[2,3-d]pyrimidin-4-1)-1H-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile are desired to provide production efficiency and reproducibility of pharmaceutical formulations and for pharmaceutical compositions with adequate stability. 2-(3-(4-(7 / 7-Pyrrole[2,3-cf]p¡r¡m¡d¡n-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azet¡d¡n-3-yl)aceton¡trl is also known by the names 2-[1-c¡cloprop¡lsulfon¡l-3-[4-(7 / - / -p¡rrol[2,3-c / ]p¡r¡m¡d¡n-4-¡l)p¡razol-1yl]azet¡n-3-yl]acetone yl 2-(1-c¡cloprop¡lsulfon¡l-3-pyrazole-1-¡l-(4-(7 / - / -p¡rrol[2,3-c / ]p¡nmid¡nazetid¡n-3yl)acetonitrile and clarity effects is the following formula (I): (i). In a preferred embodiment, compound of the invention is crystalline Form I of 2-(3-(4-(7 / - / pyrrole[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfon¡l)azetid¡n-3-l) as described herein. The crystalline form I of 2-(3-(4-(7 / - / -pyrrole[2,3-c / ]p¡r¡m¡d¡n-4-¡l)-1 / - / -pyrazol-1 -yl)-1(c¡cloprop¡lsulfon¡l)azetid¡n-3-¡l) is an anhydrogen. In another preferred embodiment, compound of the invention is crystalline form II of 2-(3-(4-(7 / - / pyrrole[2,3-c(]pyrimidin-4-yl))-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is described in crystal form II as presented in Form II. 2-(3-(4-(7 / 7-p¡rrol[2,3-c / ]p¡rimid¡n-4-¡l)-1 / - / -p¡razol-1-¡l)-1(c¡cloprop¡lsulfon¡l)azet¡dine-3-¡l)acetone is also anhydrous. In another preferred embodiment, compound of the invention is crystalline form III of 2-(3-(4-(7 / - / p¡rrolo[2,3-d]pyr¡m¡m¡n-4-¡l)-1 / - / -pyrazol-1-¡l)-1-(c¡chlopropylsulfon¡l)azet¡din-3-¡l)acetone is described in the present. Crystalline form III of 2-(3-(4-(7 / 7-pyrrole[2,3-c / ]p¡prim¡n-4-¡l)-1 / - / -pyrazol-1-11)-1(cycloprop¡lsulfonyl)azetidin-3-yl)acetonitrile is a hydrated form. Forms I, II, and III, as well as other polymorphic forms of 2-(3-(4-(7 / - / -pyrrolo[2,3c / ]pyrimidin-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile, can be characterized by X-ray diffraction. The peaks were measured using a powder diffractometer equipped with a copper source, primary beam monochromator, and position-sensitive detector. The incident beam was collimated using a 1° divergence slit. The source was operated at 40 kV and 40 mA. Powder X-ray diffraction data were collected from 2.5° to 50° using a step width of 0.02° and a step time of 37 seconds. Alternatively, the peaks were measured using a powder diffractometer equipped with a copper source, primary beam monochromator, and position-sensitive detector. The incident beam was collimated using a 1° divergence slit. The source was operated at 40 kV and 40 mA.Powder X-ray diffraction data were collected from 1.5 degrees to 50 degrees using a step width of 0.02 degrees and a step time of 12 seconds. It is recognized that the relative intensity of X-ray diffraction peaks can depend on preferred orientation and other factors such as particle size. When preferred orientation and / or particle size effects are present, peak intensities may be altered, but the peak positions characteristic of the polymorph remain unchanged. See, for example, The United States Pharmacopoeia No. 24, National Formulary No. 19, pages 1843-1844, 2000. Therefore, a sample of form I or form II or form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidine-4-1)-1 / - / -pyrazol-1 -II)-1 (cyclopropylsulfonyl)azetidine-3-1)acetonitrile may require processing to mitigate such factors, such as grinding the sample in an agate mortar or other measures.It is understood that differences in the relative intensity of diffraction peaks do not exclude that an acquired pattern is consistent with form I or form II or form III of 2-(3-(4-(7 / 7-p¡rrolo[2,3- <y]pirimid¡n-4-¡l)-1 / - / -p¡razol-1-il)-1(ciclopropilsulfonil)azetidin-3-il)acetonitrilo. Furthermore, it is also well known in crystallography that, for any given crystal form, the angular positions of the peaks can vary slightly. For example, peak positions can be displaced due to sample displacement or variations in the temperature or relative humidity at which the sample is analyzed. In the present case, a peak position variability of ±0.2° in 2Θ will account for these potential variations without hindering the unambiguous identification of the crystal form described herein. Forms I, II, or III of 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidin-4-1)-1H-pyrazol-1-1-1)-1-(cyclopropylsulfonyl)azethidine-3-1)acetonitrile can also be characterized by differential scanning calorimetry. DSC can be performed in closed (hermetically sealed) gold crucibles or in orifice-filled aluminum trays; sample filled under ambient conditions or N2 flow (for 3–10 minutes); heating rate of 10 °C / minute from -50 °C to 300 °C. Form I It was observed that the crystalline form I of 2-(3-(4-(7 / 7-pino[2,3-d]pyrimidin-4-1)-1 H-pyrazol-1 -1)-1 (cyclopropylsulfonyl)azethidine-3-1)acetonitrile has the following peaks in degrees 2-theta (°20) which have (relative power greater than approximately 10% of the largest peak, % 10 / 1100): 12.72° (43.1%), 14.04° (61.3%), 17.56° (20.8%), 20.33° (87.4%), 24.50° (100%) and 25.83° (94.9%) (± 0.2° 20). The present disclosure provides a largely polymorphically pure form I of 2-(3-(4(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -1l)-1-(cyclopropylsulfonyl)azethidine-3-yl)acetonyl characterized by the powder X-ray diffraction pattern comprising a peak at 12.72°, 14.04°, 17.56°, 20.33°, 24.50° or 25.83°20 (± 0.2° 20). More specifically, the present disclosure provides the largely polymorphically pure form I of 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile characterized by the powder X-ray diffraction pattern comprising peaks at 12.72° and 24.50° (± 0.2° 20) or comprising peaks at 20.33° and 24.50° (± 0.2° 20) or comprising peaks at 12.72° and 20.33° (± 0.2° 20). Tal como se utiliza en la presente, la expresión “forma I de 2-(3-(4-(7 / - / -pirrolo[2,3-c(]pirimidin-4-¡l)1 / - / -pirazol-1 -il)-1 -(ciclopropilsulfonil)azetidin-3-il)acetonitrilo” incluye la expresión “forma I polimórficamente pura en gran medida de 2-(3-(4-(7 / - / -pirrolo[2,3-c / ]pirimidin-4-il)-1 / - / -pirazol-1-il)-1(ciclopropilsulfonil)azetidin-3-il)aceton¡trilo”. Form II It was observed that the crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidine-4-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile has the following peaks at 2-theta degrees (°20) which have (relative power greater than approximately 10% of the largest peak, % l / l0): 5.34° (16.2%); 10.68° (26.2%); 14.26° (20.8%); 16.06° (13.5%); 16.39° (17.9%); 16.48° (18.6%); 18.26° (19.5%); 18.65° (43.4%); 19.03° (100.0%); 21.05° (10.2%); 21.15° (9.9%); 21.45° (9.0%); 21.76° (20.5%); 22.45° (9.6%); 22.68° (22.5%); 23.23° (11.1%); 23.72° (12.3%); 24.90° (11.7%); 25.08° (9.2%); 26.75° (30.7%); and 31.18° (10.1%); (±0.2° 20). The present disclosure provides a largely polymorphically pure form II of 2-(3(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile characterized by the powder X-ray diffraction pattern comprising a peak at 5.34°, 10.68°, 14.26°, 16.06°, 16.39°, 16.48°, 18.26°, 18.65°, 19.03°, 21.05°, 21.76°, 22.68°, or 26.75° (± 0.2° 20). More specifically, the present disclosure provides the largely polymorphically pure form I of 2(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1-1l)-1-(cyclopropylsulfonyl)azethidine-3-1l)acetonitrile characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 10.68° (± 0.2° 20) or comprising peaks at 18.65° and 21.76° (± 0.1° 20) or comprising peaks at 18.65° and 22.68° (± 0.1° 20) or comprising peaks at 26.75° and 21.76° (± 0.2° 20). Tal como se utiliza en la presente, la expresión “forma II de 2-(3-(4-(7 / - / -pirrolo[2,3-c / ]pirimid¡n-4-il)1 / 7-pirazol-1-¡l)-1-(ciclopropilsulfon¡l)azetidin-3-il)acetonitr¡lo incluye la expresión “forma II polimórficamente pura en gran medida de 2-(3-(4-(7H-pirrolo[2,3-c / ]pirím¡din-4-il)-1 / - / -pirazol-1 -il)-1 (c¡cloprop¡lsulfon¡l)azetid¡n-3-¡l)aceton¡tr¡lo”. Form III It was observed that the crystalline form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonitrile has the following peaks at 2-theta degrees (°20) which have (relative power greater than approximately 10% of the largest peak, % l0 / l0): 11.08° (62.3%); 12.32° (15.9%); 13.28° (13.7%); 14.06° (15.3%); 14.73° (32.8%); 17.86° (16.9%); 18.06° (46.4%); 18.27° (18.1%); 18.51° (35.2%); 18.91° (10.9%); 20.36° (15.8%); 21.48° (12.7%); 22.24° (26.9%); 22.69° (100%); 23.40° (10.2%); 24.76° (18.8%); 25.48° (55.4%); 25.97° (12.6%); 26.70° (12.5%); and 28.04° (12.8%); (± 0.2° 20). The present disclosure provides a largely polymorphically pure form III of 2-(3(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1-1l)-1-(cyclopropylsulfonyl)azetidin-3-1l)acetonitrile characterized by the powder X-ray diffraction pattern comprising a peak at 11.08°, 14.73°, 18.06°, 18.27°, 18.51°, 22.24°, 22.69°, 24.76°, 25.48° or 28.04° (± 0.2° 20). More specifically, the present disclosure provides the largely polymorphically pure form III of 2-(3-(4-(7 / 7-pyrrolo[2,3c / ]pyrimidin-4-1)-1 / - / -pyrazol-1-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile characterized by the powder X-ray diffraction pattern comprising peaks at 11.08° and 22.69°; (± 0.2° 20) or comprising peaks at 14.73° and 22.69° (± 0.2° 20) or comprising peaks at 22.69° and 25.48° (± 0.2° 20) or comprising peaks at 11.08° and 18.06° (± 0.2° 20) or comprising peaks at 11.08° and 25.48° (± 0.2° 20). As used herein, the term “form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonítrilo” includes the term “largely polymorphically pure form III of 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]p¡r¡m¡d¡n-4-¡l)-1 / 7-p¡razol-1-¡l)-1(cycloprop¡lsulfon¡l)azet¡din-3-¡l)aceton¡tril”. Those skilled in the art will appreciate that the compounds can exist as tautomers. It is understood that all tautomeric forms of the compounds of the invention are within the scope of this disclosure. The compounds of the invention also include all isotopic variations, in which at least one atom with the predominant atomic mass is replaced by an atom having the same atomic number but a different atomic mass. The use of isotopic variations (e.g., deuterium, 2H) can provide greater metabolic stability. In addition, certain isotopic variations of the compounds of the invention may incorporate a radioactive isotope (e.g., tritium, 3H, or 14C), which may be useful in tissue distribution studies of substrates or drugs. Substitution with positron-emitting isotopes, such as 11C, 18F, 15O, and 13N, may be useful in positron emission tomography (PET) studies. 3. Processes for preparing crystalline forms Processes for Form I The crystalline form I of 2-(3-(4-(7H-pyrrolo[2,3-c(pyrimidin-4-1)-1H-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile can be prepared by crystallization under controlled conditions. This disclosure also provides a process for preparing the largely polymorphically pure crystalline form I of 2-(3-(4-(7H-pyrrolo[2,3-c(pyrimidin-4-1)-1H-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile, comprising crystallizing it in a mixture of acetone and heptane as the antisolvent. In a preferred embodiment, form I of 2-(3-(4-(7 / - / -pyrrolo[2,3-cf]p¡r¡m¡d¡n-4-yl)-1Hp¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azet¡din-3-¡l)aceton¡tnlo can also be obtained by dehydrating samples of form III, usually by heating to temperatures of about 40 °C to about 80 °C under vacuum. Processes of the form II The crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile can be prepared by crystallization under controlled conditions in a solvent or a mixture of solvents. This disclosure also provides a process for preparing the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, comprising crystallizing in a solvent or a mixture of solvents further containing water and having a water activity of less than 0.7. In practice, suitable solvents are selected from the group consisting of C1-5 alcohol, C2-8 alkyl ether, C2-8 alkyl acetate, C2-5 alkyl cyanide, C3-9 alkyl ketone, and an aromatic solvent, each having an aqueous activity of less than approximately 0.7. In a preferred embodiment, the present disclosure also provides a process for preparing the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-d]pyrimidin-4-1)-1-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonityl, comprising crystallizing in a solvent or a mixture of solvents further containing water and having a water activity of less than 0.5. The use of an antisolvent may be convenient. As used in this context, an “antisolvent” refers to a solvent in which 2-(3-(4-(7 / 7-pyrrolo[2,3-d]pyrimidine-4-1)-1H-pyrazol-1-1)1-(cyclopropylsulfonyl)azetidin-3-1)acetonyl is significantly less soluble relative to the selected solvent(s). Preferably, when an antisolvent is used, it is miscible with the selected solvent. While antisolvents may be used, care should be taken to ensure that the selected antisolvent(s) do not increase the aqueous activity above the desired level. It is understood that the aqueous activity provided by the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / - / -pyrrolo[2,3-d]primidine-4-1)-1 / 7-prazol-1-1)-1-(cyclopropylsulfonyl)azetidine-3-1)acetonitrile is temperature-dependent. Higher final crystallization temperatures can tolerate higher aqueous activity. Therefore, an aqueous activity of approximately 0.7 is effective at final crystallization temperatures above approximately 40 °C. Because recoveries are higher at lower temperatures, in a preferred embodiment, the present disclosure also provides a process for preparing the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidine-4-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, comprising crystallizing in a solvent or solvent mixture having an aqueous activity of less than 0.5. Typically, an aqueous activity of about 0.5 is effective at final crystallization state temperatures below approximately 25°C. The preferred solvents are selected from the group consisting of C1-5 alcohol and C2-5 alkyl cyanide; each having an aqueous activity less than approximately 0.7. An even more preferred solvent is selected from the group consisting of C1-5 alcohol and C2-5 alkyl cyanide; each having an aqueous activity less than approximately 0.5. In one particular embodiment, the present disclosure also provides a process for preparing the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin441)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidine-34l)acetonitrile, comprising crystallizing in acetonitrile further comprising water having an aqueous activity of less than 0.7. In another particular embodiment, the present disclosure also provides a process for preparing the largely polymorphically pure crystalline form II of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin441)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azethidine-34l)acetonitrile, comprising crystallizing in acetonitrile further comprising water having an aqueous activity of less than 0.5. This disclosure also provides a process for preparing the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c(]pyrimidin-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile, comprising crystallization in acetonitrile further comprising water. Care must be taken to avoid the formation of undesired hydrated crystalline forms. Therefore, preferred embodiments for crystallization in acetonitrile further comprising water use a v / v ratio of 92-97 acetonitrile to 8-3 water; more preferably, crystallization in acetonitrile further comprising water in a v / v ratio of 95-97 acetonitrile to 5-3 water. It has been observed in practice that the use of Acetonitrile / water 96:4 (v / v) has a more favorable volumetric efficiency at temperatures below approximately 20 °C. Therefore, a further preferred process for preparing a largely polymorphically pure crystalline form II of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile comprises crystallizing in acetonitrile further comprising water in a v / v ratio of approximately 96 acetonitrile to 4 water. Optionally, the crystallization can be seeded with form II of 2-(3-(4-(7 / - / -pyrrolo[2,3c / ]p¡r¡m¡din-4-yl)-1 / - / -pyrazol-141)-1 -(c¡clopropylsulfonyl)azetidin-3-yl)acetonitrile. It is envisaged that crystallization techniques by precipitation in a solution and slurry generation are within the scope of this process. When crystallization involves complete dissolution, slow cooling at rates between 0.2 °C / minute and 0.02 °C / minute is preferred. Crystallization to obtain Form II does not require complete dissolution. Slurry processes may be used. A slurry may be formed by processing without complete dissolution or by complete dissolution followed by processing after initial precipitation. In a slurry process, the volume must be sufficient to provide a fluid slurry. The solvent volume is not critical, but it should be kept to a minimum for convenience. The water activity of the solvent(s) used must account for water, including water that may be released from a hydrated starting material.Optionally, the slurry crystallization process can be seeded with form II of 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-4-1l)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonitrile. In an embodiment not containing form II, 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-1)-1H-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile is crystallized by slurry at a temperature of approximately 50 °C or higher, with optional cooling to recover the final product. In another embodiment without form II, 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-1)-1H-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile is crystallized by slurry in a solvent at a temperature that is approximately room temperature. Optionally, crystallization can be seeded with form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c(]pyrimidin-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile. Such slurry processes generally require 2 to 14 days. Processes of Form III The crystalline form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c]pyrimidin-4-yl)-1H-pyrazol-1-11)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile can be prepared by crystallization under controlled conditions in a solvent or a mixture of solvents. This disclosure also provides a process for preparing the largely polymorphically pure crystalline form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, comprising crystallizing in a solvent or a mixture of solvents further containing water and having a water activity greater than 0.9. In practice, suitable solvents are selected from the group consisting of water, C1-5 alcohol, C2-8 alkyl acetate, C2-5 alkyl cyanide, and C3-9 alkyl ketone; each having a water activity greater than approximately 0.9. The use of an antisolvent may be convenient. As used in this context, an “antisolvent” refers to a solvent in which 2-(3-(4-(7 / - / -pyrrolo[2,3-d]p¡r¡m¡din-4-¡l)-1 / - / -p¡razol-1-¡l)1-(cyclopropylsulfon¡l)azet¡din-3-¡l)aceton¡nlo is significantly less soluble relative to the selected solvent(s). Preferably, when an antisolvent is used, it is miscible with the selected solvent. Although antisolvents can be used, care must be taken to ensure that the selected antisolvent(s) do not decrease the water activity below the desired level. A preferred solvent is selected from the group consisting of C1-5 alcohols having a water activity greater than approximately 0.9. The techniques of crystallization in solution and slurry generation are considered to be within the scope of this process. When crystallization involves complete dissolution, slow cooling at rates between 0.2 °C / minute and 0.02 °C / minute is preferred. Crystallization to obtain form III does not require complete dissolution. Slurry processes may be used. A slurry can be formed by processing without complete dissolution or by complete dissolution followed by processing after initial precipitation. In a slurry process, the volume must be sufficient to provide a fluid slurry. The solvent volume is not critical, but it should be kept to a minimum for convenience. Optionally, the slurry crystallization process can be seeded with form III of 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidine-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidine-34l)acetonitril. In an embodiment not containing form III, 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-1)-1H-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile is crystallized by slurry in a solvent having a water activity greater than 0.9 at approximately room temperature. Optionally, the crystallization can be seeded with form III of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-1)-1H-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile. Such slurry processes generally require 2 to 10 days. Care must be taken when drying form III of 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidine-4-yl)-1 / 7-pyrazol-1yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile to avoid conversion to form I, preferably under vacuum at temperatures below 20 °C. 4. Synthetic methods La presente divulgación proporciona un proceso para preparar 2-(3-(4-(7H-p¡rrolo[2,3-cf]p¡r¡m¡d¡n4-il)-1 / - / -pirazol-1 -il)-1 -(ciclopropilsulfonyl)azetidin-3-il)acetonitrilo como se representa en el Esquema A. Esquema A iviA a zuz i / un In Scheme A, step 1, a compound of formula (1) is reacted with a compound of formula (2) in the presence of a suitable catalyst to obtain a compound of formula (3). A compound of formula (1) is one where X is selected from the group consisting of tosylate, triflate, chlorine, bromine, and iodine, and Pg is a protecting group. In practice, a compound of formula (1) where X is either bromine or chlorine is preferred, with chlorine being preferred even further. Various protecting groups are suitable. The selection of appropriate protecting groups can be readily determined by someone skilled in the art. The chemistry of protecting groups can be consulted, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd ed., Wiley & Sons, Inc., New York (1999). For example, t-BOC, 2-(t-methylsilyl)ethoxymethyl, and α-pivaloyloxymethyl are useful, to name but a few. In practice, a t-BOC group is preferred.A compound of formula (2) is one in which Ri and R2 are selected independently from the group consisting of hydrogen and C1-β alkyl; or R1 and R2, together with the oxygen atoms to which they are attached and the boron atom, form a 5- to 6-membered heterocyclic ring, which is optionally substituted with 1, 2, 3, or 4 C1-4 alkyl groups. As the person skilled in the art will appreciate, the reaction depicted in step 1 is the well-known Suzuki reaction. Several suitable catalysts are available. Both nickel and palladium catalysts are useful; however, palladium catalysts are preferred. Several suitable palladium(0) and palladium(II) catalysts are known in the art. For example, tetrakls(triphenylphosphino)palladium(0), tetrakls(triphenylphosphino)palladium (II) chloride, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and dichloromethane [1,T-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (1:1). The reaction is typically carried out in a solvent, including a wide variety of organic solvents. The solvent may contain water. Suitable solvents include 1,4-dioxane, THF, 1-butanol, 1,2-dimethoxyethane (DME), 2-propanol, toluene, or ethanol, or combinations thereof. The typical palladium catalyst is used in amounts of approximately 0.01 to approximately 0.1 equivalents. The reaction is carried out in the presence of a base. Both organic and inorganic bases can be used; for example, alkali metal carbonates and alkali metal bicarbonates, as well as bases such as cesium carbonate, are used. The reaction is typically carried out at a temperature of approximately 40 °C to approximately 100 °C and generally requires 1 to 18 hours. 5. Pharmaceutical compositions This disclosure provides a pharmaceutical composition comprising 2-(3-(4-(7 / - / pyrrolo[2,3-cf]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile or a salt thereof, and an acceptable excipient. In a preferred embodiment, this disclosure provides a pharmaceutical composition comprising crystalline form I, form II, or form III of 2-(3-(4-(7 / - / -pyrrolo[2,3cf]pyrimidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile and an acceptable excipient. In another preferred embodiment, the present disclosure provides a pharmaceutical composition comprising the crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidine-4-yl)-1 / 7-pyrazol-1-11)-1-(cyclopropylsulfoni1)azetidin-3-11)acetonitrile and at least one acceptable excipient.In another preferred embodiment, the present disclosure provides a pharmaceutical composition comprising the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimadin-4-yl)-1H-pyrazol-1-yl)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitriloy and at least one acceptable excipient. The compounds of the invention can be administered alone or in the form of a composition. In practice, the compounds of the invention are usually administered in the form of compositions, i.e., mixed with at least one acceptable excipient. The proportion and nature of any acceptable excipient(s) are determined by the properties of the selected compound of the invention, the chosen route of administration, and standard practice in the veterinary and pharmaceutical fields. To carry out the treatment of a subject who needs such treatment, a compound of the invention can be administered in any form and route that makes the compound bioavailable. The compounds of the invention can be administered by various routes, including orally, particularly by means of tablets and capsules. The compounds of the invention can be administered parenterally, more particularly by inhalation, subcutaneously, intramuscularly, intravenously, intra-arterially, transdermally, intranasally, rectally, vaginally, ocularly, topically, sublingually and buccally, intraperitoneally, intraadiposally, intrathecally, and locally, for example, by means of a catheter or stent. A person skilled in the art can easily select the appropriate form and route of administration depending on the particular characteristics of the selected compound, the disorder or condition to be treated, the stage of the disorder or condition, and other relevant circumstances. The pharmaceutical compositions of the invention can be administered to the patient, for example, in the form of tablets, capsules, lozenges, papers, lozenges, wafers, elixirs, ointments, transdermal patches, sprays, inhalants, suppositories, oral, topical, or injectable anthelmintics (drenches), solutions, and suspensions. In one embodiment, the composition is adapted for oral administration, such as a tablet or capsule, or a liquid formulation, for example, a solution or suspension, adapted for oral administration. In another embodiment, the composition is adapted for oral administration, such as a chewable formulation. In yet another embodiment, the composition is a liquid or semi-solid formulation, for example, a solution or suspension, or a paste, adapted for parenteral administration. The compositions of this disclosure are prepared in a manner well known in veterinary and pharmaceutical practice and include at least one of the compounds of the invention as the active ingredient. The amount of a compound of this disclosure may be varied depending on its particular form and may conveniently be between 1% and approximately 50% of the weight of the unit dosage form. These pharmaceutical compositions are preferably formulated as a unit dosage form, each dose typically containing from approximately 0.25 mg to approximately 10 mg of a compound of the invention. One or more unit dosage forms may be taken to effect the dosage of the treatment. 6. Methods of use This disclosure provides a method for treating dermatological conditions, comprising administering an effective amount of a compound of the invention to a non-human mammal in need. In certain embodiments, this disclosure provides a method for treating dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions], comprising administering to a nonhuman mammal in need an effective amount of 2-(3-(4-(7-pyrrolo[2,3-c]pyrimidin-4-yl)-1-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile or a salt thereof. A preferred nonhuman mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a preferred embodiment, this disclosure provides a method for treating dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions], comprising administering to a non-human mammal in need an effective amount of crystalline form I or form II or form III of 2-(3-(4-(7H-pyrrolo[2,3-c(]pyrimidin-4-1)-1 / 7-pyrazol-11)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonyl. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a particularly preferred embodiment, this disclosure provides a method for treating dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions], comprising administering to a non-human mammal in need an effective amount of the crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-d]primidin-4-1)-1 / 7-pyrazol1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonyl. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a further, especially preferred embodiment, the present disclosure provides a method for treating dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions], comprising administering to a non-human mammal in need an effective amount of the largely pure polymorphic crystalline form II of 2-(3-(4-(7 / - / pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonitrile. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In certain embodiments, this disclosure provides a method for treating atopic dermatitis comprising administering to a non-human mammal in need an effective amount of 2-(3(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1)-1 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile or a salt thereof. In a preferred embodiment, this disclosure provides a method for treating atopic dermatitis comprising administering to a non-human mammal in need an effective amount of I or form II or crystalline form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-44l)-1 / - / -pyrazol-1 -yl)-1 (cyclopropylsulfoníl)azetidin-3-íl)acetonítrilo. In an especially preferred embodiment, the present disclosure provides a method of treating atopic dermatitis comprising administering to a non-human mammal in need thereof an effective amount of crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3c / ]pyrimidin-4-íl)-1 / 7-pyrazol-1-yl)-1 -(cycloprop¡lsulfon¡l)azetidin-3-¡l)acetonítrilo. In a further, especially preferred embodiment, the present disclosure provides a method for treating atopic dermatitis comprising administering to a needy nonhuman mammal an effective amount of largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-cf]pyrimidin-44l)-1 / 7-pyrazol-1l)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonityl. A preferred nonhuman mammal is a dog.In certain realizations, the dog is at least 9 months old, or at least 12 months old. In certain embodiments, this disclosure provides a method for treating pruritus associated with allergic dermatitis comprising administering to a non-human mammal in need an effective amount of 2-(3-(4-(7 / - / -pyrrolo[2,3-c]pyrimidin-4-1)-1 / - / -pyrazol-14)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile or a salt thereof. In a preferred embodiment, this disclosure provides a method for treating pruritus associated with allergic dermatitis comprising administering to a non-human mammal in need an effective amount of crystalline form I or form II or form III of 2-(3-(4-(7 / - / pyrrolo[2,3-c]pyrimidin-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile.In a particularly preferred embodiment, the present disclosure provides a method for treating pruritus associated with allergic dermatitis comprising administering to a non-human mammal in need an effective amount of crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c(]pyrimidin-4-1)-1 / -pyrazol-1-1)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile. In a further particularly preferred embodiment, the present disclosure provides a method for treating pruritus associated with allergic dermatitis comprising administering to a non-human mammal in need an effective amount of largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c(]pyrimidin-4-1)-1 / - / -pyrazol-141)-1(cyclopropylsulfonyl)azetidine-34l)acetonitidine. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. An effective dose may vary, for example, from 0.5 mg to 100 mg. The specific amounts can be determined by a specialist. Although these dosages are based on a patient weighing approximately 0.5 kg to approximately 80 kg, the physician making the diagnosis will be able to determine the appropriate dose for a patient whose weight falls outside this range. An effective dose may vary, for example, from 0.1 mg to 1.2 mg / kg of the patient, from 0.3 mg to 1.0 mg / kg of the patient, or from 0.4 mg to 0.6 mg / kg of the patient. The dosage regimen may be, for example, daily, twice daily, weekly, or monthly. In certain embodiments, this disclosure provides 2-(3-(4-(7 / - / -pyrrolo[2,3c / ]pyrimidin-44l)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azethidine-3-yl)acetonitrile or a salt thereof for use in the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus MA / a / ¿U¿1 / U1 ¿04» associated with allergic dermatitis and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a preferred embodiment, this disclosure provides crystalline form I, form II, or form III of 2-(3-(4-(7 / - / -pyrolo[2,3-d]pimidine-4-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidine-3-1)acetonitrile for use in the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a particularly preferred embodiment, this disclosure provides the crystalline form II of 2-(3-(4-(7H-pyrrolo[2,3-c(]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for use in the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a further, especially preferred embodiment, this disclosure provides the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / 7-pyrolo[2,3-c]pyrimidin-44l)-1 / 7-pyrazol-1l)-1-(cyclopropylsulfonyl)azetidine-3-1l)acetonitrile for use in the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In certain embodiments, this disclosure provides 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-41l)-1-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-11)acetonitrile or a salt thereof for use in the treatment of atopic dermatitis in a non-human mammal. In a preferred embodiment, this disclosure provides crystalline form I, form II, or form III of 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-41l)-1-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-341)acetonitrile for use in the treatment of atopic dermatitis in a non-human mammal. In a particularly preferred embodiment, the present disclosure provides the crystalline form II of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-44l)-1A7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for use in the treatment of atopic dermatitis in a non-human mammal.In a further, especially preferred embodiment, the present disclosure provides the largely polymorphically pure crystalline form II of 2-(3-(4-(7H-pyrrolo[2,3-c(1-pyrimidin-441)-1-pyrazol-141)-1-(cyclopropylsulfonyl)azetidine-341)acetonitrile for use in the treatment of atopic dermatitis in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In certain embodiments, this disclosure provides 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile or a salt thereof for use in the treatment of pruritus associated with allergic dermatitis in a non-human mammal. In a preferred embodiment, this disclosure provides crystalline form I, form II, or form III of 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-4-yl)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-341)acetonitrile for use in the treatment of pruritus associated with allergic dermatitis in a non-human mammal. In a particularly preferred embodiment, the present disclosure provides the crystalline form II of 2-(3-(4-(7 / - / -pyrrolo[2,3c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for use in the treatment of pruritus associated with allergic dermatitis in a non-human mammal.In a further, especially preferred embodiment, the present disclosure provides the largely polymorphically pure crystalline form II of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for use in the treatment of pruritus associated with allergic dermatitis in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In certain embodiments, this disclosure provides for the use of 2-(3-(4-(7 / - / pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile or a salt thereof for the manufacture of a medicament for the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a preferred embodiment, this disclosure provides for the use of crystalline form I, form II, or form III of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-44l)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for the production of a medicament for the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis, and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a particularly preferred embodiment, this disclosure provides for the use of crystalline form II of 2-(3-(4-(7 / - / -pyrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3 / 1)acetonitrile for the production of a medicament for the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In a further, especially preferred embodiment, this disclosure provides for the use of the largely polymorphically pure crystalline form II of 2-(3-(4-(7H-pyrrolo[2,3-c(1primidin-4-yl)-1Hpyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonyl for the production of a medicament for the treatment of dermatological conditions [e.g., skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis), pruritus, including pruritus associated with allergic dermatitis and allergic reactions] in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In certain embodiments, this disclosure provides for the use of 2-(3-(4-(7H-pyrrolo[2,3c]pyrimidin-4-1)-1H-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-341)acetonitrile or a salt thereof for the manufacture of a medicament for the treatment of atopic dermatitis in a non-human mammal. In a preferred embodiment, this disclosure provides for the use of crystalline form I, form II, or form III of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-1)-1-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-341)acetonitrile for the manufacture of a medicament for the treatment of atopic dermatitis in a non-human mammal. In a particularly preferred embodiment, the present disclosure provides the use of the crystalline form II of 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-4-yl)-1H-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for the manufacture of a medicament for the treatment of atopic dermatitis in a non-human mammal.In a further, especially preferred embodiment, this disclosure provides for the use of the largely polymorphically pure crystalline form II of 2-(3-(4(7H-pyrrolo[2,3-c]pyrimidin-4-yl)-1H-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for the manufacture of a medicament for the treatment of atopic dermatitis in a non-human mammal. A preferred non-human mammal is a dog. In certain embodiments, the dog is at least 9 months old, or at least 12 months old. In certain embodiments, this disclosure provides for the use of 2-(3-(4-(7H-pyrrolo[2,3c]pyrimidin-44l)-1H-pyrazol-14l)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile or a salt thereof for the manufacture of a medicament for the treatment of pruritus associated with allergic dermatitis in a non-human mammal. In a preferred embodiment, this disclosure provides for the use of crystalline form I, form II, or form III of 2-(3-(4-(7H-pyrrolo[2,3c]pyrimidin-4-yl)-1H-pyrazol-14l)-1-(cyclopropylsulfonyl)azetidin-34l)acetonitrile for the manufacture of a medicament for the treatment of pruritus associated with allergic dermatitis in a non-human mammal.In a particularly preferred embodiment, this disclosure provides for the use of crystalline form II of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for the manufacture of a medicament for the treatment of pruritus associated with allergic dermatitis in a non-human mammal. In a further particularly preferred embodiment, this disclosure provides for the use of the largely polymorphically pure crystalline form II of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile for the manufacture of a medicament for the treatment of pruritus associated with allergic dermatitis in a non-human mammal. A preferred non-human mammal is a dog. In certain realizations, the dog is at least 9 months old, or at least 12 months old. 7. Examples The following examples are provided to illustrate the invention and are not intended to be limiting in any way. Example 1 2-[1-Cyclopropylsulfoníl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-íl]azetidin-3-íl]acetonitrile 2-(1-cyclopropylsulfonylazetidine-3-ylidene)acetonitrile (850 g) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 / - / -pyrazole (874 g) were combined in acetonitrile (2.6 L). 1,8-Diazabicyclo[5,4,0]undec-7ene (65 g) was added, and the mixture was heated to 70 °C. After 2.5 hours, the reaction mixture was cooled to room temperature for approximately 2 hours. Water (5.2 L) was slowly added to the mixture over approximately 1 hour, and the mixture was stirred for approximately 3 hours. The solid that formed was collected by filtration and dried under vacuum at 45 °C for approximately 24 hours to obtain 2-[1-cyclopropylsulfonyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile. Example 2 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-¡l)-1 H-pyrazol-1 -yl)-1 -(c¡clopropylsulfonyl)azet¡din-3-¡l)acetonitrile Potassium phosphate (829 g) was combined with water (1 L) and cooled to room temperature. THF (2 L) was added. 4-Chloropyrrolo[2,3-c(]pyrimidine] (200 g) was added, followed by the addition of di-tert-butyl dicarbonate (344 g). The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was bubbled through nitrogen gas for 60 minutes. 2-[1-cyclopropylsulfonyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile (562 g) and Pd-134 (6.6 g) were added, and the reaction temperature was raised to 60 °C. After approximately 2 hours, the aqueous layer separated, and silica thiol (40 g) was added. The reaction was stirred at 60 °C for 18 hours.The reaction mixture was filtered at 60 °C and then the filtrate was cooled to 10-20 °C with stirring to obtain a solid which was collected by filtration and rinsed with cold THF before drying at 40-50 °C under vacuum for 2 hours to obtain tert-butyl 4-[1-[3-(cyanomethyl)-1-cyclopropylsulfonylazetidine-3-yl]pyrazol-4-yl]pyrrolo[2,3cf]pyrimidin-7-carboxylate (540 g). The previously obtained tert-butyl 4-[1-[3-(cyanomethyl)-1-cyclopropylsulfonylazethidine-3-1]pyrazol-4-1]pyrlo[2,3-d]pyrimidin-7-carboxylate (540 g) was combined with n-butanol (3 L) and water (770 mL) and heated to 90 °C. After 6 hours, the reaction was cooled to 80 °C in 30 minutes and then stirred at 80 °C for 30 minutes before being cooled to 20 °C for 6 hours and stirred at 10-20 °C for 16 hours to obtain a solid which was filtered to obtain 460 g of the title compound (as a wet mass). Example 3 2-(3-(4-(7H-Pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 H-pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile Potassium phosphate (829 g) was combined with water (1 L) and cooled to room temperature. THF (2 L) was added. 4-Chloropyrrolo[2,3-c(]primidine (200 g) was added, followed by the addition of di-tert-butyl dicarbonate (344 g). The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was bubbled through nitrogen gas for 60 minutes. 2-[1-cyclopropylsulfonyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-11)pyrazol-1-11]azetidin-3-11]acetonitrile (562 g) and Pd-134 (6.6 g) were added, and the reaction temperature was raised to 60 °C. After approximately 2 hours, the aqueous layer separated, and silica thiol (40 g) was added, and the reaction was stirred at 60 °C for 18 hours.The reaction mixture was filtered at 60 °C and then the filtrate was cooled to 10-20 °C with stirring to obtain a solid which was collected by filtration and rinsed with cold THF before drying at 40-50 °C under vacuum for 2 hours to obtain fert-butyl 4-[1-[3-(cyanomethyl)-1-cyclopropylsulfonylazetidin-3-yl]pyrazol-4-yl]pyrrolo[2,3d]pyrimidine-7-carboxylate (525 g). The previously obtained fert-butyl 4-[1-[3-(cyanomethyl)-1-cyclopropylsulfonylazetidine-3-yl]pyrazol-4-yl]pyrrolo[2,3-cf]pyrimidin-7-carboxylate (540 g) was combined with n-butanol (3 L) and water (770 mL) and heated to 90 °C. After 6 hours, the reaction was cooled to 80 °C in 30 minutes and then stirred at 80 °C for 30 minutes before being cooled to 20 °C for 6 hours and stirred at 10-20 °C for 16 hours to obtain a solid which was filtered to obtain 454 g of the title compound (as a wet mass). Example 4 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3¡l)acetonítrilo Form II The wet masses from Examples 2 and 3 (approximately 907 g) were combined in acetonitrile (4 L) and stirred at 60 °C for 2 hours. The reaction mixture was cooled to 20 °C for 6 hours and then stirred at 20 °C for 12 hours. The solid was collected by filtration, washed with acetonitrile, and dried under vacuum at 50–60 °C for 24 hours to obtain the title compound (695 g). Example 5 2-(3-(4-(7 / - / -Pyrrolo[2,3-cf]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form I 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile (104.1 mg) was combined with acetone (8 mL) and heated to 55 °C. After 30 minutes, the reaction mixture was cooled at a rate of 0.02 °C / minute to a temperature of 30 °C and then at a rate of 0.1 °C / minute to a temperature of 5 °C while simultaneously adding heptane (12 mL) at a rate of 2.94 mL / hour to obtain a solid which was collected by filtration and dried to obtain the title compound (79.5 mg). Example 6 2-(3-(4-(7H-Pyrrolo[2,3-c(]p¡r¡m¡din-4-yl)-1 H-pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 H-pyrazol-1 -yl)-1-(cyclopropylsulfonyl)azetidin-3 was combined IVIA a ZUZ I ¿04» il)acetonitrile (152.4 mg) with acetonitrile (8.1 mL) and was heated to 80 °C. After 30 minutes, the reaction mixture was cooled at a rate of 0.05 °C / minute to a temperature of 5 °C to obtain a solid that was collected by filtration and dried to obtain the title compound (93.4 mg). Example 7 2-(3-(4-(7 / - / -Plrrolo[2,3-c / ]p¡r¡m¡n-4-¡l)-1 / - / -p¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azetidin-3¡l)acetonitrile Form II 2-(3-(4-(7H-pyrrolo[2,3-c(]pimidine-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3 / 1)acetonitrile (157.8 mg) was combined with acetonitrile / water 96:4 (v / v) (4.2 mL) and heated to 80 °C. After 30 minutes, the reaction mixture was cooled at a rate of 0.05 °C / minute to a temperature of 5 °C to obtain a solid which was collected by filtration and dried to obtain the title compound (89.4 mg). Example 8 Form II of 2-(3-(4-(7H-Plrrolo[2,3-c / ]p¡r¡m¡din-4-¡l)-1 / 7-p¡razol-1 -yl)-1 -(cycloprop¡lsulfon¡l)azetidin-3yl)acetonítrilo 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3yl)acetonitrilo (5 g) was combined with acetonitrile / water 96:4 (v / v) (100 mL) and heated up to 80 °C. After approximately 75 minutes, the reaction mixture was cooled at a rate of 0.20 °C / minute to a temperature of 70 °C. Seeds (two 0.25 g portions) were then added, and cooling was continued at a rate of 0.05 °C / minute to a temperature of 8 °C to obtain a solid. After approximately 6 hours, the solid was collected by filtration and dried to obtain the title compound (4.88 g). Example 9 Form II of 2-(3-(4-(7 / - / -Pyrrolo[2,3-c(]p¡r¡m¡d¡n-4-¡ l)-1 / - / -pyrazol-1 -yl)-1 -(cycloprop¡lsulfon¡l)azetidin-3¡l)acetonitrile 2-(3-(4-(7 / - / -pyrolo[2,3-c / ]pimidine-4-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile (20.6 mg) is combined with methanol / water 4:1 (v / v) (0.3 mL) having an aqueous activity of approximately 0.5 and stirred at 25 °C for 4 days, more methanol / water 4:1 (v / v) (0.5 mL) is added and stirring continues at 25 °C for 6 days, and then the solid is collected by filter centrifugation (3 minutes, 5000 rpm, 0.2 pm PVDF membrane) to obtain the title compound. Example 10 Form II of 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-íl)-1 / - / -pyrazole-141)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (10 g) was combined with acetonitrile / water 96:4 (v / v) (250 mL) and heated to 72 °C. After approximately 60 minutes, the reaction mixture was cooled at a rate of 0.20 °C / minute to a temperature of 65 °C, then seeds (0.10 g) were added, and cooling was continued at a rate of 0.035 °C / minute to a temperature of 35 °C to obtain a solid, and then at a rate of 0.125 °C / minute to a temperature of 5 °C to obtain a solid. MA / a / ¿U¿1 ¿04» approximately 3 hours, the solid was collected by filtration and dried to obtain the title compound (8.51 g). Example 11 Form II of 2-(3-(4-(7 / - / -ΡΙ rrolo[2,3-c / ]pyrimid in-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonítril 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidin-4-yl)-1 / - / -pyrazol-141)-1-(cyclopropylsulfonyl)azethidine-3-yl)acetonitrile (70.3 mg) was combined with 0.2 mL of acetone / water 9:1 (v / v) and heated to 60 °C while stirring. More acetone / water 9:1 (v / v) was slowly added to a total of approximately 1.6 mL. The temperature was maintained at 60 °C for 1.5 hours, and then the mixture was cooled at a rate of 0.05 °C / minute to 10 °C and held at 10 °C for 2 hours and 45 minutes to obtain a solid. The solid was collected by filter centrifugation (2 minutes, 5000 rpm) to obtain the title compound. Example 12 2-(3-(4-(7 / 7-Pyrrolo[2,3-c / ]p¡r¡m¡d¡n-44l)-1 / - / -pyrazol-141)-1-(cycloprop¡lsulfon¡l)azetidin-3yl)aceton¡trilo Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3¡l)acetonitrile (149.8 mg) was combined with acetonitrile (8.0 mL) and heated to 80 °C. After 30 minutes, the reaction mixture was cooled at a rate of 0.02 °C / minute to a temperature of 55 °C. The reaction mixture was then cooled at a rate of 0.1 °C / minute in the range of 55 °C to 5 °C while simultaneously adding a total of 12 mL of isopropyl acetate at a rate of 1.44 mL / hour for the same duration as the cooling ramp from 55 °C to 5 °C to obtain a solid that was collected by filtration and dried to obtain the title compound (94.2 mg). Example 13 Form II of 2-(3-(4-(7 / 7-Pyrrolo[2,3-c(]p¡ñm¡din-4-¡ l)-1 / 7-pyrazol-141)-1 -(cycloprop¡lsulfonyl)azetidine-3¡l)acetonitrile 2-(3-(4-(7- / -pyrrolo[2,3-c / ]pyrimidin-44l)-1- / -pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-31l)acetonitrile (208.5 mg) was combined with 0.2 mL of 3:1 methanol / water (v / v) and heated to 60 °C while stirring. More 3:1 methanol / water (v / v) was slowly added to a total of approximately 23.2 mL. The temperature was maintained at 60 °C for 30 minutes, and then the mixture was cooled at a rate of 0.05 °C / minute to 10 °C and held at 10 °C for 20 minutes to obtain a solid. The solid was collected by filtration to obtain the title compound. Example 14 Form III of 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]píñmidín-4-yl)-1 / - / -pyrazole-141)-1 -(cyclopropylsulfoníl)azetídin-3yl)acetonítrilo 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-44l)-1 / - / -pyrazol-141)-1 -(cyclopropylsulfonyl)azetidin-3¡l)acetonitrile (60 mg) is combined with 2 mL of 1-butanol / water 5:1 (v / v) having an aqueous activity of approximately 0.9 and is stirred at room temperature for 10 days and then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. MA / a / ¿U¿1 / U1 ¿04» Example 15 2-(3-(4-(7 / 7-Pírrolo[2,3-c / ]p¡nm¡n-4-¡l)-1 / 7-p¡razol-1-yl)-1-(cycloprop¡lsulfon¡l)azet¡din-3yl)acetonitrile Form III 2-(3-(4-(7 / - / -pyrolo[2,3-d]p¡nm¡d¡n-4-¡l)-1 / 7-p¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azet¡d¡n-3¡l)acetonitrile (33 mg) is combined with 0.4 mL of methanol / water 3:2 (v / v) having an aqueous activity of approximately 0.7 and stirred at approximately 20 °C for 14 days and then the solid is collected by filter centrifugation (2 minutes, 4400 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 16 Form II of 2-(3-(4-(7 / - / -Pyrrolo[2,3-c(]p¡r¡m¡din-4-¡l)-1 / 7-p¡razol-1-¡l)-1-(c¡cloprop¡lsulfon¡l)azet¡din-3yljacetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (60.4 mg) is combined with acetophenone (1 mL) and shaken at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 17 2-(3-(4-(7 / - / -Pyrrolo[2,3-c(]pyrimídin-4-íl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidine-3íl)acetonitrile Form II 2-(3-(4-(7 / 7-pyrrolo[2,3-c(]pyrimidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azethidine-3-yl)acetonitrile (59.9 mg) is combined with butyronitrile (2 mL) and shaken at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 18 Form II of 2-(3-(4-(7 / - / -Pí rrolo[2,3-d]p¡nm¡d in-4-yl )-1 H-pyrazol-1 -yl)-1 -(cyclopropylsulfon¡l)azet¡din-3yl)acetonitrile 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azethidine-3-1)acetonitrile (60.3 mg) is combined with cyclohexanone (1.5 mL) and shaken at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 19 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-íl)-1 / 7-pyrazole-1-íl)-1-(cyclopropylsulfoníl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonitrile (60.9 mg) is combined with dioxane (2 mL) and shaken at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 20 2-(3-(4-(7H-Pyrrolo[2,3-c(]pyr¡m¡din-4-yl)-1 H-pyrazol-1-11)-1 -(cyclopropylsulfon¡l)azet¡din-3-yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]p¡nmid¡n-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (60.0 mg) is combined with ethyl formate (1.5 mL) and shaken at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 21 2-(3-(4-(7 / - / -Pyrrolo[2,3-c(]pyrimidin-4-¡l)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-cy]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (59.4 mg) is combined with methyl acetate (1.5 mL) and shaken at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 22 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-¡l)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azet¡din-3¡l)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (60.5 mg) is combined with nitrobenzene (2 mL) and shaken at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 23 2-(3-(4-(7 / - / -P¡rrolo[2,3-c / ]p¡nm¡n-4-¡l)-1 / - / -p¡razol-1-¡l)-1-(cycloprop¡lsulfonyl)azet¡din-3¡l)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c(|p¡r¡m¡n-4-¡l)-1 / - / -pyrazol-1-yl)-1-(cycloprop¡lsulfon¡l)azetid¡n-3¡l)acetonitrile (60.5 mg) is combined with anisole (0.6 mL) and shaken at 40 °C for 6 days and then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 24 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1-1l)-1-(cyclopropylsulfonyl)azetidin-3-1l)acetonitrile (59.8 mg) is combined with ethyl formate (0.6 mL) and shaken at 40 °C for 6 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.22 pm PVDF membrane) to obtain the title compound. Example 25 2-(3-(4-(7 / - / -Pírrolo[2,3-c / ]pyrimídin-4-íl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfoníl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c(|pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (60.5 mg) is combined with isopropyl acetate (0.6 mL) and shaken at 40 °C for 6 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.22 pm PVDF membrane) to obtain the title compound. Example 26 2-(3-(4-(7 / - / -Pírrolo[2,3-d]p¡r¡m¡n-4-¡l)-1 / 7-p¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azet¡din-3¡l)acetonite Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-cf]pyrimidin-4-1l)-1 / - / -pyrazol-1-1l)-1-(cyclopropylsulfonyl)azetidin-3-1l)acetonitrile (60.4 mg) is combined with isopentanol (1 mL) and shaken at 40 °C for 6 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 27 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azet¡din-3¡l)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidinM-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile (60.4 mg) is combined with methyl isobutyl ketone (1 mL) and shaken at 40 °C for 6 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.22 pm PTFE membrane) to obtain the title compound. Example 28 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / 7-pyrazol-1-íl)-1-(cyclopropylsulfoníl)azetidin-3yl)acetonítril Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3¡l)acetonitrile (60.6 mg) is combined with ethanol / water 3:1 (v / v) having an aqueous activity of approximately 0.7 (0.9 mL) and stirred at 40 °C for 6 days and then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.22 pm PVDF membrane) to obtain the title compound. Example 29 2-(3-(4-(7 / - / -Plrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfoníl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azethidine-3-1)acetonitrile (69.7 mg) was combined with 1-propanol (10.8 mL) and heated to 60 °C while stirring. Dimethyl sulfoxide (2 mL) was slowly added to approximately an 85:15 (v / v) 1-propanol / DMSO mixture. The temperature was maintained at 60 °C for approximately 1.5 hours and then the mixture was cooled at a rate of 0.05 °C / minute to 10 °C and maintained at 10 °C for 7.5 hours then 1-propanol (5 mL) was added and then the mixture was stirred at 5 °C for 10 days to obtain a solid which was collected by filtration to obtain the title compound. Example 30 Form III of 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]p¡r¡m¡d¡n-4-yl)-1 / 7-p¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azetidin-3yl)acetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidine-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (70.6 mg) is combined with water-saturated ethyl acetate (0.2 mL) and heated to 60 °C while stirring, then ethyl acetate (7.2 mL) is added and stirred at 60 °C for approximately 1.5 hours, then the mixture is cooled at a rate of 0.05 °C / minute to 10 °C, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 31 Form III of 2-(3-(4-(7 / 7-Pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]p¡r¡m¡n-4-¡l)-1 / - / -pyrazol-1-¡l)-1-(cycloprop¡lsulfon¡l)azetid¡n-3iL)acetonitrile (199.6 mg) is combined with water-saturated ethyl acetate (2.0 mL) and stirred at room temperature for 2 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 32 Form I of 2-(3-(4-(7 / 7-Pyrrolo[2,3-c / ]p¡r¡m¡din-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form III of 2-(3-(4-(7 / 7-pyrolo[2,3-c / ]pyrimidin-4-1)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitril obtained from the material of Example 31 by vacuum drying at 60 °C for approximately 69 hours to obtain the title compound. Example 33 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidín-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]p¡r¡m¡d¡n-4-¡l)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfon¡l)azet¡d¡n-3¡l)acetonitrile (60.3 mg) is combined with ethanol (1 mL) and shaken at 5 °C for 7 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 34 2-(3-(4-(7 / 7-Pyrrolo[2,3-c / ]pyrimidin-4-¡l)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (60.4 mg) is combined with methanol (1 mL) and shaken at 5 °C for 7 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 35 2-(3-(4-(7 / - / -Pírrolo[2,3-c / ]pyrimidin-4-íl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-1)-1 / 7-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile (60.0 mg) is combined with isopropanol (1 mL) and shaken at 5 °C for 7 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 36 Form II of 2-(3-(4-(7 / 7-Pírrolo[2,3-c / ]pyrámídin-4-íl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropílsulfoníl)azetidin-3yl)acetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]p¡r¡m¡d¡n-4-¡l)-1 / 7-p¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azet¡d¡n-3yljacetonitrile (60.3 mg) is combined with 1-butanol (2 mL) and shaken at 5 °C for 7 days and then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 37 2-(3-(4-(7 / - / -Pyrrolo[2,3-GI]pyrimidín-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2I3-c / ]pyrimidin-4-i)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3i)acetonitrile (59.6 mg) is combined with ethanol (1 mL) and shaken at 60 °C for 5 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 38 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-íl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7H-pyrrolo[2,3-c(|p¡r¡midin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (59.9 mg) is combined with methanol (1 mL) and shaken at 60 °C for 5 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 39 Form II of 2-(3-(4-(7 / - / -Pírrolo[2,3-c / ]píhmidín-4-íl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfoníl)azetidin-3íl)acetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (60.1 mg) is combined with isopropanol (1.5 mL) and shaken at 60 °C for 5 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 40 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]p¡r¡m¡din-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfon¡l)azetidin-3¡l)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azethidine-3-yl)acetonitrile (60.6 mg) is combined with 1-butanol (1.5 mL) and shaken at 60 °C for 5 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.45 pm PVDF membrane) to obtain the title compound. Example 41 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrim¡din-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pimidine-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile (10.4 mg) is combined with acetonitrile (0.5 mL) and shaken at 20 °C for 1 day, then the solid is collected by filter centrifugation (1 minute, 4500 g rcf, 0.2 pm PTFE membrane) to obtain the title compound. Example 42 2-(3-(4-(7 / 7-Pyrrolo[2,3-c / ]p¡r¡m¡n-4-¡l)-1 / 7-p¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azet¡din-3yl)acetonitrile Form II 2-(3-(4-(7H-pyrrolo[2,3-c / ]p¡r¡m¡n-4-¡l)-1 / - / -p¡razol-14l)-1-(cyclopropylsulfon¡l)azetid¡n-3yl)acetonitrile (10.3 mg) is combined with acetone (0.5 mL) and shaken at 20 °C for 1 day, then the solid is collected by filter centrifugation (2 minutes, 4000 g rcf, 0.2 pm PTFE membrane) to obtain the title compound. Example 43 Form II of 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonítrilo 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidine-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile (20.6 mg) is combined with methanol / water 4:1 (v / v) having an aqueous activity of approximately 0.5 (0.4 mL) and stirred at 25 °C for 4 days, then more methanol / water 4:1 (v / v) (0.5 mL) is added and stirred at 25 °C for 6 days and then the solid is collected by filter centrifugation (3 minutes, 5000 rpm, 0.2 pm PVDF membrane) to obtain the title compound. Example 44 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]p¡r¡m¡d¡n-4-¡l)-1 / 7-p¡razol-1-¡l)-1-(cycloprop¡lsulfon¡l)azet¡din-3¡l)acetonitrile Form II 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3¡I)acetonitrile (539.9 mg) is combined with ethanol / acetone 1:1 (v / v) (18 mL) and stirred at 60 °C for 45 minutes, then cooled at a rate of 0.05 °C / minute to a temperature of 5 °C to obtain a solid that was collected by filtration and vacuum dried at 40 °C to obtain the title compound. Example 45 Form II of 2-(3-(4-(7 / - / -Pyrrolo[2,3-c / ]pyrimidín-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3¡l)acetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-1l)acetonitrile (256.1 mg) is combined with acetone / isopropyl acetate 7:3 (v / v) (13.5 mL) and stirred at 60 °C for 1 hour and then cooled at a rate of 0.02 °C / minute to a temperature of 5 °C to obtain a solid that was collected by filtration and vacuum dried at 40 °C to obtain the title compound. Example 46 Form III of 2-(3-(4-(7 / - / -Pyrrolo[2,3-d]p¡r¡m¡din-4-yl)-1 / 7-pyrazol-1-¡l)-1-(cycloprop¡lsulfon¡l)azetidin-3yl)acetonitrile 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3 iviAazuz i / ui il)acetonitrile (60 mg) is combined with 1-butanol / water 5:1 (v / v) having an aqueous activity of approximately 0.9 (2 mL) and stirred at room temperature for 10 days, then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 47 2-(3-(4-(7 / 7-Pírrolo[2,3-c / ]p¡nm¡n-4-¡l)-1 / 7-pyrazol-1-¡l)-1-(cycloprop¡lsulfonyl)azet¡din-3yl)acetonitrile Form III 2-(3-(4-(7H-pyrrolo[2,3-c / ]p¡r¡m¡d¡n-4-¡l)-1 / - / -p¡razol-14l)-1-(cycloprop¡lsulfon¡l)azet¡d¡n-3yl)acetonitrile (60.1 mg) is combined with acetonitrile / water 1:1 (v / v) having an aqueous activity of approximately 0.9 (0.9 mL) and stirred at 40 °C for 6 days and then the solid is collected by filter centrifugation (2 minutes, 5000 rpm, 0.2 pm PTFE membrane) to obtain the title compound. Example 48 Control of pruritus and skin lesions associated with allergic dermatitis in dogs In this study, 2-(3-(4-(7 / 7-pyrrolo[2,3-d]p¡r¡m¡n-44l)-1 / - / -pyrazol-1-yl)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile was evaluated for the control of pruritus and skin lesions associated with allergic dermatitis in dogs. Oral tablets containing Form II of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile were prepared as follows. Oral tablet mixtures were prepared containing the Crystalline Form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c(|pyrimidin4-i I)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfoni I)azetidi η-3-yl)acetonitrile, microcrystalline cellulose, pregelatinized starch, dehydrated dicalcium phosphate, oxide pigment, and magnesium stearate. The tablet mixtures were compressed to obtain tablet cores containing 2.4 mg, 3.6 mg, 5.4 mg, and 16 mg of the Crystalline Form II of 2-(3-(4-(7 / 7-pyrrolo[2,3-c(|p¡r¡m¡n-4-¡l)-1 / - / -p¡razol-1-¡l)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, as well as a placebo core. The tablet cores were coated with a mixture containing water and Opadry 20A150011 Red, thus obtaining the final oral tablets for the study. IVIA / a / ¿U¿ I ¿04» Table 1. Tablet mixtures Ingredient Amount (% w / w) Placebo Amount (% w / w) 2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-11)-1H-pyrazol-1-11)-1-(cyclopropylsulfonyl)azetidin-3-11)acetonitrile 2.4 Microcrystalline Cellulose (Vivapur 302) 52.0 52.0 Pregelatinized Starch (Starch 1500) 12.0 12.0 Dicalcium Phosphate Dehydrate (Di Tab) 32.4 34.8 Oxide Pigment RED PB-150021 0.2 0.2 Magnesium Stearate (Hyqual) 1.0 1.0 A four-group, blinded, randomized, placebo-controlled study was conducted to evaluate the efficacy of daily administration of 2-(3-(4-(7H-pyrolo[2,3-d]primidin-4-1)-1H pyrazol-1-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1-1)acetonitrile for the control of pruritus and skin lesions associated with allergic dermatitis in dogs. Subjects were randomly assigned to one of the following treatment groups: Tablets containing API, 0.25-0.40 mg / kg body weight; Tablets containing API, 0.40-0.60 mg / kg body weight; Tablets containing API, 0.60-0.80 mg / kg body weight; and Placebo tablets, 0.0 mg / kg body weight. The dogs included in the study received treatment once daily for approximately 28 days. Baseline data (medical history, concurrent therapies, body weight, physical examinations, and assessments of pruritus and atopic dermatitis) were collected for each dog at enrollment (Day 0). Additional health assessments, physical examinations, body weight measurements, pruritus and atopic dermatitis assessments, and blood sample collection for hematologic, serum chemistry, and pharmacokinetic (PK) analysis were performed according to standard testing protocols. The primary efficacy variable was treatment success. Treatment success was defined as a reduction of 2 or more units from baseline on the owner-rated 10-unit visual analogue scale (VAS) for pruritus in at least 70% of the first 7 days of treatment (i.e., in at least 5 of the first 7 days of treatment). Dogs withdrawn from the study within the first 7 days of treatment due to perceived lack of effectiveness were considered treatment failures. The minimum effective dose was defined in the protocol as the dose at which treatment success was achieved in at least 50% of the dogs. Table 2 shows that the highest dose of 2-(3-(4-(7H-pyrrolo[2,3-djp / inmidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-1-yl)acetonitrile (0.60–0.80 mg / kg) had a response rate of 0.7188 (95% confidence interval: 0.5331, 0.8512), which is statistically significantly higher than the placebo response rate of 0.2935 (0.1571, 0.4808); the p-value for the comparison (on the logit scale) is 0.0006. Therefore, the highest dose group (0.6–0.8 mg / kg) met the primary endpoint for treatment success. Furthermore, once-daily dosing at 0.6–0.8 mg / kg showed significant improvements in pruritus from the first dose, and the group showed a significant improvement in lesion scores by day 28 of the study. The estimated mean marginal response rate for low (0.24–0.4 mg / kg) and medium (0.4–0.6 mg / kg) doses was also higher than the placebo rate.This result is based on a generalized linear mixed model with fixed effects terms for treatment and Day 0 VAS score. Random effects were fitted for site and site treatment with a variance component covariance structure and a compound symmetry covariance structure was fitted for individual dogs. Table 2. Summary of the generalized linear mixed model for treatment success Treatment group Number of dogs Mean least squares Standard error 95% confidence limits p-value vs placebo 0.25-0.40 mg / kg 43 0.4640 0.0919 (0.2900, 0.6472) 0.1336 0.40-0.60 mg / kg 42 0.5590 0.0891 (0.3772, 0.7261) 0.0227 0.60-0.80 mg / kg 42 0.7188 0.0809 (0.5331, 0.8512) 0.0006 Placebo 0.0 mg / kg 42 0.2935 0.0824 (0.1571, 0.4808) 8. Exemplary achievements For the sake of completeness, several aspects of disclosure are set out in the following numbered clauses. Clause 1. A polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1-1l)-1-(cyclopropylsulfonyl)azetidin3-1l)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising a peak at 12.72° (43.1%), 14.04° (61.3%), 17.56° (20.8%), 20.33° (87.4%), 24.50° (100%) and 25.83° (94.9%) (± 0.2° 20). Clause 2. A pharmaceutical composition comprising the largely pure polymorphically pure 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile of Clause 1 and a pharmaceutically acceptable excipient. Clause 3. A process to prepare polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrmidin-4-yl)-1 / - / -pyrazol-1 -yl)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile in the middle of Clause 1, which includes crystallization in acetone and heptane. Cláusula 4. Un proceso para preparar el 2-(3-(4-(7 / 7-pirrolo[2,3-c / ]p¡rimidin-4-il)-1 / - / -pirazol-1 -il)-1(ciclopropilsulfonil)azetidin-3-¡l)acetonitrilo cristalino polimórficamente puro en gran medida de la Cláusula 1, que comprende secar una forma cristalina hidratada de 2-(3-(4-(7 / - / -pirrolo[2,3-c / ]pirimidin-4-¡l)-1 / - / pirazol-1-¡l)-1-(ciclopropilsulfonil)azetidin-3-il)acetonitrilo. Clause 5. A method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of the largely pure polymorphically pure 2-(3-(4-(7 / - / -pyrrolo[2,3-tf]p¡r¡m¡n-4-yl)-1 Hpyrazol-1 -yl)-1 -(cycloprop¡lsulfon¡l)azetid¡n-3-¡l)acetonitrile crystalline compound of Clause 1. Clause 6. The method of Clause 5, wherein the dermatological condition is selected from the group consisting of atopic dermatitis and pruritus. Clause 7. The method of Clause 6, where the non-human mammal is a dog. Clause 8. A largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin3-yl)acetonitrile characterized by the powder X-ray diffraction pattern comprising a peak at 5.34°, 10.68°, 14.26°, 16.06°, 16.39°, 16.48°, 18.26°, 18.65°, 21.05°, 21.76°, 22.68° or 26.75° (± 0.2° 20). Clause 9. A polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1)-1 / - / -pyrazol-1-1-1)-1-(cyclopropylsulfonyl)azetidin3-1)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 10.68° (± 0.2° 20). Clause 10. A polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -11)-1-(cyclopropylsulfonyl)azethidine-3-yl)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 21.76° (± 0.2° 20). Clause 11. A largely pure, polymorphically crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-14l)-1(c¡clopropylsulfon¡l)azetidin-3-¡l)acetonítrile characterized by the powder X-ray diffraction pattern comprises peaks at 18.65° and 22.68° (± 0.2° 2Θ). Clause 12. A 2-(3-(4-(7H-pyrrole[2,3-c / ]p¡r¡m¡d¡n-4-¡l)-1 / - / -pyrazole-1 41)-1(c¡cloprop¡lsulfon¡l)azetid¡n-3-lcrystalline polycrystalline acetone) largely pure characterized by the powder X-ray diffraction pattern comprising peaks at 26.75° and 21.76° (± 0.2° 20). Clause 13. A pharmaceutical composition comprising a 2-(3-(4-(7 / - / -pyrrole[2,3-c / ]pyrim¡d¡n441)-1 / - / -pyrazole-141)-1 -(c¡cloprop¡lsulfonyl)azet¡dl¡n¡n¡n-34 crystallocene) polymorphically pure substantially from any one of Clauses 8-12 and a pharmaceutically acceptable excipient. Clause 14. A process for preparing a largely polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pᵣᵣᵣn-4-λ)-1 / 7-pᵣazol-14λ)-1-(cyclopropylsulfonyl)azetidᵣn-3-λ)acetonitrile from any one of Clauses 8-12, comprising crystallizing in a solvent or mixture of solvents selected from the group consisting of C1-5 alcohol, C2-8 alkyl ether, C2-8 alkyl acetate, C2-5 alkyl cyanide, C3-9 alkyl ketone, and aromatic solvent; each having an aqueous activity of less than approximately 0.7. Clause 15. A process for preparing a largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile from any one of Clauses 8-12, comprising crystallizing in a solvent or mixture of solvents selected from the group consisting of C1-5 alcohol, C2-8 alkyl ether, C2-8 alkyl acetate, C2-5 alkyl cyanide, C3-9 alkyl ketone, and aromatic solvent; each having an aqueous activity of less than about 0.5. Clause 16. A process for preparing a 2-(3-(4-(7 / - / -pyrolo[2,3-d]pyrimidin-44l)-1 / 7-pyrazol-141)-1(cyclopropylsulfonyl)azetidine-34l)acetonitrile polymorphically pure to a large extent from any one of Clauses 8-12, comprising crystallizing in acetonitrile having an aqueous activity of less than 0.7. Clause 17. A process for preparing a largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-141)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile from any one of Clauses 8-12, comprising crystallizing in acetonitrile having an aqueous activity of less than 0.5. Clause 18. A method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-d]p¡r¡m¡n-4-yl)-1 Hp¡razol-14l)-1-(cycloprop¡lsulfon¡l)azetid¡n-34l)acetonitrile from any one of Clauses 8-12. Clause 19. The method of Clause 18, wherein the dermatological condition is selected from the group consisting of atopic dermatitis and pruritus. Clause 20. The method of Clause 19, where the non-human mammal is a dog. Cláusula 21. Un 2-(3-(4-(7H-pirrolo[2,3-cf]p¡r¡m¡d¡n-4-il)-1 H-pirazol-141)-1(ciclopropilsulfon¡l)azetidin-34l)acetonitr¡lo cristalino polimórficamente puro en gran medida caracterizado por el patrón de difracción de rayos X de polvo que comprende un pico a 11.08°, 14.73°, 18.06°, 18.27°, 18.5 Γ, 22.24°, 22.69°, 24.76°, 25.48° or 28.04° (± 0.2° 20). Cláusula 22. A 2-(3-(4-(7H-pyrrolo[2,3-c / ]p¡rimidin-44l)-1 H-pyrazol-1-yl)-1(c¡cloprop¡lsulfonyl)azetidin-3-yl)acetonitrile polymorphically pure crystalline material characterized by the patronage of dust X-ray difraction including peaks at 11.08° and 22.69° (± 0.2° 20). Cláusula 23. Un 2-(3-(4-(7H-pirrolo[2,3-cf]p¡rim¡d¡n-44l)-1 H-pirazol-1 41)-1(c¡cloprop¡lsulfonil)azet¡d¡n-34l)aceton¡tr¡lo cristalino polimórficamente puro en gran medida caracterizado por el patrón de difracción de rayos X de polvo que comprende picos a 14.73° y 22.69° (± 0.2° 20). Clause 24. A largely polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-44l)-1 / - / -pyrazol-1-yl)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile characterized by the X-ray powder diffraction pattern comprising peaks a 22.69° and 25.48° (± 0.2° 20). Clause 25. A polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3-c / ]pyrimidin-44l)-1 H-pyrazol-1 41)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising peaks at 11.08° and 18.06° (± 0.2° 20). Clause 26. A polymorphically pure 2-(3-(4-(7H-pino[2,3-c]pyrimidin-44l)-1 H-pyrazol-141)-1(cyclopropylsulfonyl)azetidin-3-l)acetonitrile crystalline largely characterized by the powder X-ray diffraction pattern comprising peaks at 11.08° and 25.48° (± 0.2° 20). Clause 27. A pharmaceutical composition comprising a largely polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin441)-1 H-pyrazol-1 -yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile of any one of Clauses 21-26 and a pharmaceutically acceptable excipient. Clause 28. A process for preparing 2-(3-(4-(7H-pyrrolo[2,3-c(]pyrimidin-44l)-1H-pyrazol-14l)-1-(cyclopropylsulfonyl)azetidin-3-l)acetonitrile polymorphically pure to a large extent from any one of Clauses 21-26, comprising crystallizing in a solvent or a mixture of solvents selected from the group consisting of C1-5 alcohol, C2-8 alkyl ether, C2-8 alkyl acetate, C2-5 alkyl cyanide and C3-9 alkyl ketone; each having an aqueous activity greater than about 0.9. Clause 29. A process for preparing largely polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidine-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile from any one of Clauses 21-26, comprising crystallizing in a solvent or mixture of solvents selected from the group consisting of C1-5 alcohol having an aqueous activity greater than about 0.9. Clause 30. A method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of crystalline 2-(3-(4-(7H-pyrrolo[2,3-c / ]p¡r¡d¡n-4-¡l)-1Hpyrazol-141)-1 -(cyclopropylsulfon¡l)azetidin-3-¡l)acetonitn from any one of Clauses 2126. Clause 31. The method of Clause 30, wherein the dermatological condition is selected from the group consisting of atopic dermatitis and pruritus. Clause 32. The method of Clause 31, where the non-human mammal is a dog. Cláusula 33. A 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-44l)-1H-pyrazol-14l)-1iviAazuz 1 / un ¿04a (cyclopropylsulfonyl)azetidin-3-yl)acetonitrile crystalline polymorphically pure in a large medium characterized by the Dust 26.75° (± 0.2° 2Θ). Cláusula 34. The 2-(3-(4-(7 / 7-pyrrolo[2,3-d]pirim¡d¡n-4-yl )-1 / - / -pyrazol-1 -11)-1 (cycloprop¡lsulfon¡l)azet¡din-3-¡l)acetone¡tr¡lo polymorphically pure crystalline medium clause 33, characterized by the difraction pattern of dust X-rays which includes peaks at 18.65° and 10.68° (±0.2° 20). Clause 35. Polymorphically pure crystalline 2-(3-(4-(7 / - / -p¡rrolo[2,3-d]p¡rimid¡n-44l)-1 / - / -pyrazol-14l)-1(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile polymorphically pure within the meaning of clause 33, characterized by the dust X-ray difraction pattern which includes peaks at 18.65° and 21.76° (±0.2° 20). Cláusula 36. The 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]p¡r¡mid¡n-4-yl)-1 / - / -pyrazol-1 41)-1(cycloprop¡lsulfon¡l)azet¡d¡n-34l)acetonitr¡lo crystalline polymorphically pure in large quantities clause 33, characterized by the dust X-ray difraction pattern which includes peaks at 18.65° and 22.68° (±0.2° 20). Cláusula 37. Polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyr¡m¡din-4-yl)-1 / - / -pyrazol-1-yl)-1(cyclopropylsulfon¡l)azetid¡n-3-yl)acetonitrile polymorphically pure in the middle of the clausula 33, characterized by the dust X-ray difraction pattern which includes peaks at 26.75° and 21.76° (±0.2° 20). Clause 38. A pharmaceutical composition comprising a largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c(]pyrimidine441)-1 / - / -pyrazol-1 -yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile of any one of clauses 33 to 37 and a pharmaceutically acceptable excipient. Clause 39. A process for preparing 2-(3-(4-(7 / - / -pyrolo[2,3-d]pyrimidin-4-1)-1 / - / -pyrazol-1-11)-1 (cyclopropylsulfonyl)azetidine-34l)acetonitrile polymorphically pure to a large extent from any one of Clauses 33 to 37, comprising crystallizing in a solvent or a mixture of solvents selected from the group consisting of C1-5 alcohol, C2-8 alkyl ether, C2-8 alkyl acetate, C2-5 alkyl cyanide, C3-9 alkyl ketone and aromatic solvent; each having an aqueous activity of less than about 0.7. Clause 40. A process for preparing largely polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-c]pyrimidin-4-yl)-1 / - / -pyrazol-14l)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonitrile from any one of Clauses 33 to 37, comprising crystallizing in a solvent or a mixture of solvents selected from the group consisting of C1-5 alcohol, C2-8 alkyl ether, C2-8 alkyl acetate, C2-5 alkyl cyanide, C3-9 alkyl ketone, and aromatic solvent; each having an aqueous activity of less than about 0.5. Clause 41. A process for preparing largely polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-1)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile from any one of Clauses 33 to 37, comprising crystallizing in acetonitrile having an aqueous activity of less than 0.7. Clause 42. A process for preparing 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile polymorphically pure to a large extent from any one of Clauses 33 to 37, comprising crystallizing in acetonitrile having an aqueous activity of less than 0.5. Clause 43. A method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-yl)-1-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile or a salt thereof. Clause 44. A method for controlling pruritus associated with allergic dermatitis and controlling atopic dermatitis, comprising administering to a non-human mammal in need an effective amount of 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3yl)acetonitrile or a salt thereof. Clause 45. A method of treating pruritus associated with allergic dermatitis, comprising administering to a non-human mammal in need an effective amount of 2-(3-(4-(7 / - / -pyrrolo[2,3c / ]pyrimidin-4-1l)-1 / - / -pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile or a salt thereof. Clause 46. A method of treating the clinical manifestations of atopic dermatitis, comprising administering to a non-human mammal in need an effective amount of 2-(3-(4-(7 / - / pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1 -yl)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonitrile or a salt thereof. Clause 47. The method of any one of clauses 43-46, where the non-human mammal is a dog. Clause 48. The method of clause 47, where the dog is at least 12 months old. Clause 49. The method of any one of clauses 43-48, where the effective amount is 0.6-0.8 mg / kg. Clause 50. The method of any one of clauses 43-49, where administration to the non-human mammal is once a day. Clause 51. The method of any one of clauses 43-50, where 2-(3-(4-(7 / 7-pyrrolo[2,3c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is crystalline. Clause 52. The method of any one of clauses 43-51, where 2-(3-(4-(7 / 7-pyrrolo[2,3c / ]pyrimidín-4-íl)-1 / - / -pyrazol-1-yl)-1-(cyclopropílsulfonyl)azetidin-3-yl)acetonitrile is Crystal Form I, Crystal Form II, Crystal Form III or any combination of these. Clause 53. The method of any one of clauses 43-51, wherein the 2-(3-(4-(7 / - / -pyrrolo[2,3c / ]pyrimidin-4-yl)-1 / 7-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is a polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising a peak at 5.34°, 10.68°, 14.26°, 16.06°, 16.39°, 16.48°, 18.26°, 18.65°, 21.05°, 21.76°, 22.68° or 26.75° (± 0.2° 20). Clause 54. The method of any one of clauses 43-51, wherein the 2-(3-(4-(7 / 7-pyrrolo[2,3cf]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is a polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3cf]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 10.68° (±0.2° 20). Clause 55. The method of any one of clauses 43-51, wherein the 2-(3-(4-(7H-pyrrolo[2,3c]pyrimidin-4-yl)-1 H-pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is a polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3d]pyrimidin-4-yl)-1 H-pyrazol-1 -yl )-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 21.76° (±0.2° 20). Cláusula 56. El método de una cualquiera de las cláusulas 43-51, donde el 2-(3-(4-(7H-pirrolo[2,3c / ]p¡r¡m¡din-4-¡l)-1 H-pirazol-1-il)-1-(c¡cloprop¡lsulfon¡l)azet¡d¡n-3-¡l)aceton¡tr¡lo es un 2-(3-(4-(7H-pirrolo[2,3c(]p¡r¡m¡din-4-¡l)-1 H-pirazol-1 -il)-1 -(ciclopropilsulfonil)azetidin-3-il)acetonitrilo cristalino polimórficamente puro en gran medida caracterizado por el patrón de dust X-ray difraction including peaks at 18.65° and 22.68° (±0.2° 20). Cláusula 57. The method of a cualquiera de las clausulas 43-51, where the 2-(3-(4-(7H-pyrrolo[2,3c / ]pyrimidin-4-jl)-1 H-pyrazol-1 -yl)-1 -(c¡clopropylsulfonyl)azetidin-3-yl)acetonitrile is a 2-(3-(4-(7H-pyrrolo[2,3c / ]pirim¡din-4-¡l)-1 H-pyrazol-1 -yl)-1-(c¡clopropylsulfonyl)azetid¡n-3-yl)acetonitrile polymorphically pure crystalline medium characterized by the design of X-ray difraction of polvo that includes pics a 26.75° and 21.76° (±0.2° 20). Clause 58. An oral pharmaceutical form comprising 2-(3-(4-(7H-p¡rrolo[2,3-d]pyrim¡din-4-¡l)1 H-pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-¡l)acetone or a starch salt. Clause 59. An oral pharmaceutical form comprising 2-(3-(4-(7H-pyrrole[2,3-c(]pyrimidin-4-yl)1 H-pyrazol-1-11)-1-(cyclopropylsulfonyl)azet¡din-3-yl)aceton¡tr¡l. Clause 60. An oral pharmaceutical form comprising 2-(3-(4-(7H-pyrrole[2,3-c / ]p¡r¡m¡n-4-¡l)1 H-pyrazol-1 -yl)-1 -(cyclopropylsulfonyl)azetidin-3-yl)acetonyl crystalline. Clause 61. An oral pharmaceutical form comprising 2.4 mg, 3.6 mg, 4.8 mg, 5.4 mg, 6.4 mg, 8.5 mg, 15 mg or 16 mg of 2-(3-(4-(7H-pyrrole[2,3-c(|p¡prim¡d¡n-4-¡l)-1H-p¡razol-1-¡l)-1(cycloprop¡lsulfon¡l)azetid¡n-3-¡l)aceton¡tr¡l. Cláusula 62. La forma farmacéutica oral de una cualquiera de las cláusulas 58-61, donde el 2-(3(4-(7H-p¡rrolo[2,3-d]pirimidin-4-¡l)-1 H-pirazol-1 -il)-1 -(ciclopropilsulfonil)azetidin-3-il)acetonitrilo es la Forma I, Forma II o Forma III de 2-(3-(4-(7H-pirrolo[2,3-c(|pirim¡din-4-il)-1H-pirazol-1-il)-1(ciclopropilsulfonil)azetidin-3-il)acetonitrilo, o una combinación de estas. Cláusula 63. La forma farmacéutica oral de una cualquiera de las cláusulas 58-62, donde el 2-(3(4-(7H-pirrolo[2,3-c / ]pirimidin-4-¡l)-1 H-pirazol-1 -il)-1 -(ciclopropilsulfonil)azetidin-3-il)acetonitrilo es 2-(3-(4(7H-pirrolo[2,3-c(|p¡r¡m¡d¡n-4-¡l)-1 H-pirazol-1 -il)-1 -(ciclopropilsulfonil)azetidin-3-il)acetonitrilo cristalino polimórficamente puro en gran medida caracterizado por el patrón de difracción de rayos X de polvo que comprende un pico at 5.34°, 10.68°, 14.26°, 16.06°, 16.39°, 16.48°, 18.26°, 18.65°, 21.05°, 21.76°, 22.68° or 26.75° (± 0.2° 2Θ). Clause 64. The oral pharmaceutical form of any one of Clauses 58-63, wherein the oral pharmaceutical form further comprises microcrystalline cellulose, pregelatinized starch, dehydrated dicalcium phosphate, magnesium oxide pigment or magnesium stearate, or any combination thereof. MA / a / ¿U¿1 / UI ¿04» It is hereby stated that, as of this date, the best method known to the applicant for putting the aforementioned invention into practice is the one that is clear from the present description of the invention.

Claims

1. A process for preparing a polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3-cf]pyrimidin-4-1)-1H-pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising a peak at 5.34°, 10.68°, 14.26°, 16.06°, 16.39°, 16.48°, 18.26°, 18.65°, 21.05°, 21.76°, 22.68° or 26.75° (± 0.2° 20), the process comprising crystallization in a solvent selected from the group consisting of a C1-5 alcohol, an ether of a C2-8 alkyl, a C2-8 alkyl acetate, a C2-5 alkyl cyanide, a C3-9 alkyl ketone and an aromatic solvent or a mixture thereof; wherein the solvent or mixture of solvents has an aqueous activity of less than 0.

7.

2. The process according to claim 1, wherein the largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrim id i n441)-1 / - / -pyrazol-1 -yl)-1-(cyclopropylsulfonyl)azetidine-3-yl)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 10.68° (± 0.2° 20).

3. The process according to claim 1, wherein the largely polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-d]pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 21.76° (±0.2° 2Θ).

4. The process according to claim 1, wherein the largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin441)-1 / - / -pyrazol-1-1)-1-(cyclopropylsulfonyl)azetidin-3-1)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 22.68° (± 0.2° 20).

5. The process according to claim 1, wherein the largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-c / ]pyrimidin441)-1 / - / -pyrazol-1-1l)-1-(cyclopropylsulfonyl)azetidin-3-1l)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 26.75° and 21.76° (± 0.2° 20).

6. The process according to any one of claims 1 to 5, wherein the solvent or mixture of solvents has a water activity of less than approximately 0.

5.

7. The process according to any one of claims 1 to 5, wherein the crystallization is in acetonitrile having an aqueous activity less than 0.

7.

8. The process according to any one of claims 1 to 5, wherein the crystallization is in acetonitrile having an aqueous activity of less than 0.

5.

9. A method for treating a dermatological condition comprising administering to a non-human mammal in need an effective amount of polymorphically pure crystalline 2-(3-(4-(7 / 7-pyrrolo[2,3-c / ]pyrimidin-4-yl)-1 / - / -pyrazol-1-yl)-1 (cyclopropylsulfonyl)azetidin-3-yl)acetonitrile largely characterized by the powder X-ray diffraction pattern comprising a peak at 5.34°, 10.68°, 14.26°, 16.06°, 16.39°, 16.48°, 18.26°, 18.65°, 21.05°, 21.76°, 22.68° or 26.75° (± 0.2° 20).

10. The method according to claim 9, wherein the largely polymorphically pure crystalline 2-(3-(4-(7 / - / -pyrrolo[2,3-cf]p¡r¡m¡n-4 il)-1 H-pyrazol-141)-1 -(cyclopropylsulfonyl)azetidin-34l)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 10.68° (±0.2° 2Θ).

11. The method according to claim 9, wherein the largely polymorphically pure crystalline 2-(3-(4-(7H-pyrolo[2,3-cf]pyrimidin-4l)-1H-pyrazol-141)-1-(cyclopropylsulfonyl)azetidin-34l)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 21.76° (± 0.2° 2Θ).

12. The method according to claim 9, wherein the largely polymorphically pure crystalline 2-(3-(4-(7H-pyrolo[2,3-d]pyrimidin-4l)-1H-pyrazol-14l)-1-(cyclopropylsulfonyl)azetidine-34l)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 18.65° and 22.68° (± 0.2° 2Θ).

13. The method according to claim 9, wherein the largely polymorphically pure crystalline 2-(3-(4-(7H-pyrrolo[2,3-c(1p¡r¡midin-4yl)-1 H-pyrazol-1-yl)-1 -(cycloprop¡lsulfon¡l)azet¡din-34l)acetonitrile is characterized by the powder X-ray diffraction pattern comprising peaks at 26.75° and 21.76° (±0.2° 20).

14. The method according to any one of claims 9 to 13, wherein the dermatological condition is atopic dermatitis or pruritus.

15. The method according to claim 14, wherein the non-human mammal is a dog.